Heat Biologics to Present at the 2018 BIO International Convention

DURHAM, NC / ACCESSWIRE / May 30, 2018 / Heat Biologics, Inc. HTBX, a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced its Chief Executive Officer, Jeff Wolf, will present a
corporate overview at the 2018 BIO International Convention on Wednesday, June 6^th, at 2:45 PM, Eastern Time, held at the Boston Convention and Exhibition Center in Boston, MA.

The BIO International Convention allows for public and private companies to provide formal presentations, request face-to-face meetings with biotech investors and executives, attend educational sessions and engage in networking opportunities. For more information, please visit: http://convention.bio.org/about-bio-convention/.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.